Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) is now available.
Shanghai Pharmaceuticals Holding Co., Ltd. announced a significant change in its shareholder structure, as Shanghai Shangshi Yangtze River Delta Ecological Development Co., Ltd. transferred its 40% equity interest in Shanghai Pharmaceutical (Group) Co., Ltd. to Shanghai Shangshi (Group) Co., Ltd. for RMB6,721.5148 million. This transaction results in Shanghai Shangshi (Group) Co., Ltd. holding 100% of Shanghai Pharmaceutical (Group), which is a controlling shareholder of Shanghai Pharmaceuticals Holding Co., Ltd. The change is expected to have implications for the company’s governance and strategic direction, as well as affecting its market positioning and stakeholder relationships.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$14.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. operates in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products. The company is a major player in the Chinese market, with a significant shareholding structure that involves various stakeholders.
Average Trading Volume: 4,060,084
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$76.68B
See more data about 2607 stock on TipRanks’ Stock Analysis page.